Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription


1 Am J Case Rep
1 Am J Transl Res
2 Arch Toxicol
5 BMC Cancer
1 Cancer Biomark
1 Cancer Lett
1 Cancer Med
1 Cell Death Dis
1 Chin Clin Oncol
1 Eur Urol Open Sci
1 Front Med (Lausanne)
1 Front Oncol
1 Front Surg
1 Hum Pathol
1 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 J Anesth
1 J Biomed Opt
1 J Cancer
1 J Cell Physiol
1 J Exp Clin Cancer Res
1 Microsc Res Tech
2 Oncoimmunology
1 Oncol Res Treat
1 Pharm Res
1 Scand J Urol
2 Sci Rep
3 Urol J
2 Urologe A
1 Urologia
1 World J Surg Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Case Rep

  1. VALLILAS C, Zachou M, Dolkiras P, Sakellariou S, et al
    Difficulties in Diagnosing and Treating Disseminated Bacillus Calmette-Guerin (BCG) Infection After Intravesical BCG Therapy in a Patient with Liver Cirrhosis: A Case Report.
    Am J Case Rep. 2021;22:e933006.
    PubMed         Abstract available

    Am J Transl Res

  2. LIN Y, Zhang Y, Luo L, Zhang X, et al
    Clinical effect of robot-assisted radical cystectomy in bladder cancer.
    Am J Transl Res. 2021;13:10545-10553.
    PubMed         Abstract available

    Arch Toxicol

  3. LEGGETT CS, Doll MA, States JC, Hein DW, et al
    Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes.
    Arch Toxicol. 2021;95:311-319.
    PubMed         Abstract available

  4. MA L, Zhang D, Huang Z, Zheng R, et al
    Functional variants of RPS6KB1 and PIK3R1 in the autophagy pathway genes and risk of bladder cancer.
    Arch Toxicol. 2021 Oct 19. pii: 10.1007/s00204-021-03173.
    PubMed         Abstract available

    BMC Cancer

  5. COLLING R, Colling H, Browning L, Verrill C, et al
    Validation of grading of non-invasive urothelial carcinoma by digital pathology for routine diagnosis.
    BMC Cancer. 2021;21:995.
    PubMed         Abstract available

  6. GRIVAS P, Loriot Y, Morales-Barrera R, Teo MY, et al
    Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
    BMC Cancer. 2021;21:593.
    PubMed         Abstract available

  7. VERGHOTE F, Poppe L, Verbeke S, Dirix P, et al
    Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    BMC Cancer. 2021;21:1113.
    PubMed         Abstract available

  8. WANG M, Ren X, Wang G, Sun X, et al
    Construction of a survival prediction model for high-and low -grade UTUC after tumor resection based on "SEER database": a multicenter study.
    BMC Cancer. 2021;21:999.
    PubMed         Abstract available

  9. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor.
    BMC Cancer. 2021;21:604.
    PubMed         Abstract available

    Cancer Biomark

  10. HUSSEIN S, Fathi A, Abouhashem NS, Amer S, et al
    SATB-1 and Her2 as predictive molecular and immunohistochemical markers for urothelial cell carcinoma of the bladder.
    Cancer Biomark. 2021;30:249-259.
    PubMed         Abstract available

    Cancer Lett

  11. CHOW PM, Chang YW, Kuo KL, Lin WC, et al
    CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaive and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Cancer Lett. 2021;507:70-79.
    PubMed         Abstract available

    Cancer Med

  12. WANG X, Yu J, Chen J, Hou Y, et al
    Copy number variation analysis of m(6) A regulators identified METTL3 as a prognostic and immune-related biomarker in bladder cancer.
    Cancer Med. 2021 Oct 20. doi: 10.1002/cam4.3981.
    PubMed         Abstract available

    Cell Death Dis

  13. YI L, Wang H, Li W, Ye K, et al
    The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer.
    Cell Death Dis. 2021;12:944.
    PubMed         Abstract available

    Chin Clin Oncol

  14. ROGERS JE, Ajani JA
    The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma.
    Chin Clin Oncol. 2021;10:30.

    Eur Urol Open Sci

  15. MASON J, Hasnain Z, Miranda G, Gill K, et al
    Prediction of Metastatic Patterns in Bladder Cancer: Spatiotemporal Progression and Development of a Novel, Web-based Platform for Clinical Utility.
    Eur Urol Open Sci. 2021;32:8-18.
    PubMed         Abstract available

    Front Med (Lausanne)

  16. MAO C, Xu X, Ding Y, Xu N, et al
    Optimization of BCG Therapy Targeting Neutrophil Extracellular Traps, Autophagy, and miRNAs in Bladder Cancer: Implications for Personalized Medicine.
    Front Med (Lausanne). 2021;8:735590.
    PubMed         Abstract available

    Front Oncol

  17. FAN B, Huang Y, Wen S, Teng Q, et al
    Predictive Value of Preoperative Positive Urine Cytology for Development of Bladder Cancer After Nephroureterectomy in Patients With Upper Urinary Tract Urothelial Carcinoma: A Prognostic Nomogram Based on a Retrospective Multicenter Cohort Study and
    Front Oncol. 2021;11:731318.
    PubMed         Abstract available

    Front Surg

  18. SUGEETA SS, Sharma A, Ng K, Nayak A, et al
    Biomarkers in Bladder Cancer Surveillance.
    Front Surg. 2021;8:735868.
    PubMed         Abstract available

    Hum Pathol

  19. GUPTA R, Epstein JI
    Plasma cell neoplasms of the bladder: a series of 9 cases.
    Hum Pathol. 2021;111:52-58.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

    Expression of Editorial Concern: Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:e457-e462.
    Int J Radiat Oncol Biol Phys. 2021;111:1094.

    Int J Urol

  21. NARITA T, Hatakeyama S, Numakura K, Kobayashi M, et al
    Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
    Int J Urol. 2021;28:899-905.
    PubMed         Abstract available

  22. HARADA M, Tomisaki I, Minato A, Onishi R, et al
    Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
    Int J Urol. 2021;28:970-974.
    PubMed         Abstract available

    J Anesth

  23. HUH H, Lee SW, Cho JE, Kim HC, et al
    Effect of chlorpheniramine administration on postoperative catheter-related bladder discomfort in patients undergoing transurethral excision of bladder tumor: a prospective randomized study.
    J Anesth. 2021;35:646-653.
    PubMed         Abstract available

    J Biomed Opt

  24. XU Z, Zhu H, Wang H
    Segmentation of the urothelium in optical coherence tomography images with dynamic contrast.
    J Biomed Opt. 2021;26.
    PubMed         Abstract available

    J Cancer

  25. MO L, Xu L, Jia M, Su B, et al
    Shikonin suppresses the epithelial-to-mesenchymal transition by downregulating NHE1 in bladder cancer cells.
    J Cancer. 2021;12:6814-6824.
    PubMed         Abstract available

    J Cell Physiol

  26. YAN Q, Chen BJ, Hu S, Qi SL, et al
    Emerging role of RNF2 in cancer: From bench to bedside.
    J Cell Physiol. 2021;236:5453-5465.
    PubMed         Abstract available

    J Exp Clin Cancer Res

  27. ZHANG M, Wang L, Yue Y, Zhang L, et al
    ITPR3 facilitates tumor growth, metastasis and stemness by inducing the NF-kB/CD44 pathway in urinary bladder carcinoma.
    J Exp Clin Cancer Res. 2021;40:65.
    PubMed         Abstract available

    Microsc Res Tech

  28. KLORIN G, Halachmi S, Nativ O, Massalha Y, et al
    Morphometric analysis of nuclear symmetry in urothelial carcinoma for predicting tumor recurrence.
    Microsc Res Tech. 2021;84:2559-2564.
    PubMed         Abstract available


  29. JIN H, D'Urso V, Neuteboom B, McKenna SD, et al
    Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.
    Oncoimmunology. 2021;10:1958590.
    PubMed         Abstract available

  30. WANG L, Jiang G, Jing N, Liu X, et al
    Downregulating testosterone levels enhance immunotherapy efficiency.
    Oncoimmunology. 2021;10:1981570.
    PubMed         Abstract available

    Oncol Res Treat

  31. MAYER K, Briese W, Blieninger J, Brossart P, et al
    Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis.
    Oncol Res Treat. 2021;44:538-546.
    PubMed         Abstract available

    Pharm Res

  32. CE R, Lavayen V, Couto GK, De Marchi JGB, et al
    Folic Acid-Doxorubicin-Double-Functionalized-Lipid-Core Nanocapsules: Synthesis, Chemical Structure Elucidation, and Cytotoxicity Evaluation on Ovarian (OVCAR-3) and Bladder (T24) Cancer Cell Lines.
    Pharm Res. 2021;38:301-317.
    PubMed         Abstract available

    Scand J Urol

  33. ANDERSEN CS, Thoft Jensen B, Nielsen Holck E, Kingo PS, et al
    Prospective versus retrospective recordings of comorbidities and complications in bladder cancer patients undergoing radical cystectomy - a randomized controlled trial.
    Scand J Urol. 2021 Oct 16:1-6. doi: 10.1080/21681805.2021.1987978.
    PubMed         Abstract available

    Sci Rep

  34. CHAN KM, Gleadle J, Li J, Michl TD, et al
    Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors.
    Sci Rep. 2021;11:7283.
    PubMed         Abstract available

  35. IDE H, Kikuchi E, Ogihara K, Niwa N, et al
    Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history.
    Sci Rep. 2021;11:20675.
    PubMed         Abstract available

    Urol J

  36. TAKAHARA K, Sumitomo M, Ito M, Ito F, et al
    Predictors of Secondary Bladder Cancer in Patients with Prostate Cancer Treated with Brachytherapy: A Single-institution Study of a Japanese Cohort.
    Urol J. 2021 Oct 13. pii: 6718. doi: 10.22037/uj.v18i.6718.
    PubMed         Abstract available

  37. PARTOVIPOUR E, Roshandel G, Motlagh A, Salavati F, et al
    Bladder Cancer Incidence in Iran: Results of the Iranian National Population-Based Cancer Registry from 2014 to 2016.
    Urol J. 2021 Oct 13. pii: 6760. doi: 10.22037/uj.v18i.6760.
    PubMed         Abstract available

  38. CHUNG JW, Kim JW, Lee EH, Chun SY, et al
    Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette-Guerin and the Relationship with the CUETO Scoring Model.
    Urol J. 2021 Oct 16. pii: 6765. doi: 10.22037/uj.v18i.6765.
    PubMed         Abstract available

    Urologe A

  39. GAKIS G
    [Prophylaxis of recurrence in low-to-intermediate risk non-muscle invasive bladder cancer (NMIBC)].
    Urologe A. 2021 Oct 15. pii: 10.1007/s00120-021-01680.
    PubMed         Abstract available

  40. VON LANDENBERG N, Benderska-Soder N, Bismarck E, Kernig K, et al
    [Rational follow-up of non-muscle invasive bladder cancer].
    Urologe A. 2021 Oct 15. pii: 10.1007/s00120-021-01683.
    PubMed         Abstract available


  41. GUPTA S, Dutta A, Pal DK
    Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG.
    Urologia. 2021 Oct 20:3915603211050783. doi: 10.1177/03915603211050783.
    PubMed         Abstract available

    World J Surg Oncol

  42. GAO Z, Wu D, Zheng W, Zhu T, et al
    Prognostic value of immune-related lncRNA pairs in patients with bladder cancer.
    World J Surg Oncol. 2021;19:304.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.